<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289155</url>
  </required_header>
  <id_info>
    <org_study_id>GX-I7_TP</org_study_id>
    <nct_id>NCT04289155</nct_id>
  </id_info>
  <brief_title>Individual Patient Compassionate Use of GX-I7</brief_title>
  <official_title>Individual Patient Compassionate Use of GX-I7</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <brief_summary>
    <textblock>
      Compassionate use of GX-I7 for patients with serious life-threatening illness that have
      exhausted all available therapies, with no other therapy options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program is being offered on a patient by patient basis and will require company,
      Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Glioblastoma</condition>
  <condition>High Grade Glioma</condition>
  <condition>Recurrent Glioblastoma</condition>
  <condition>Melanoma</condition>
  <condition>Advanced Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>patients will receive the assigned dose of GX-I7 intramuscular injection every 4~12 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Minkyu Heo</last_name>
    <phone>+82 31 628 3340</phone>
    <email>mkheo@genexine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

